Cancer is the second leading cause of death worldwide and is a major global health burden. Significant improvements in survival have been achieved, due in part to advances in adjuvant antineoplastic chemotherapy. The most commonly used antineoplastics belong to the taxane, platinum, and vinca alkaloid families. While beneficial, these agents are frequently accompanied by severe side effects, including chemotherapy-induced peripheral neuropathy (CPIN). While CPIN affects both motor and sensory systems, the majority of symptoms are sensory, with pain, tingling, and numbness being the predominant complaints. CPIN not only decreases the quality of life of cancer survivors but also can lead to discontinuation of treatment, thereby adversely affecting survival. Consequently, minimizing the incidence or severity of CPIN is highly desirable, but strategies to prevent and/or treat CIPN have proven elusive. One difficulty in achieving this goal arises from the fact that the molecular and cellular mechanisms that produce CPIN are not fully known; however, one common mechanism appears to be changes in ion channel expression in primary afferent sensory neurons. The processes that underlie chemotherapy-induced changes in ion channel expression and function are poorly understood. Not all antineoplastic agents directly affect ion channel function, suggesting additional pathways may contribute to the development of CPIN Indeed, there are indications that these drugs may mediate their effects through cellular signaling pathways including second messengers and inflammatory cytokines. Here, we focus on ion channelopathies as causal mechanisms for CPIN and review the data from both pre-clinical animal models and from human studies with the aim of facilitating the development of appropriate strategies to prevent and/or treat CPIN.
Introduction
Cancer (all sites) presents an enormous global disease burden. In 2015, 17.5 million new cases were diagnosed, and there were 8.7 million cancer deaths. The lifetime risk of developing cancer is one in three for men and one in four for women. In men, prostate cancer was the most common, while cancers of the trachea, bronchi, and lung were the leading causes of cancer death. In women, breast cancer was the most common cancer as well as the leading cause of cancer deaths. 1 Treatment options are tumor and patient specific, and routinely include, alone or in combination, surgery, radiation therapy, immunomodulatory therapy, and adjuvant antineoplastic chemotherapy. Among the antineoplastics commonly encountered in the aforementioned settings are those belonging to the taxane, platinum, and vinca alkaloid families. [2] [3] [4] [5] [6] Although efficacious, these agents are associated with significant, debilitating, adverse side effects, including chemotherapy-induced peripheral neuropathy (CIPN). As cancer survival rates have improved, 1, 7 the burden of CIPN has correspondingly increased. CIPN can affect both sensory and motor systems and has a profound negative impact on long-term quality of life (QoL). [8] [9] [10] [11] There is evidence that patients deem CIPN to be so unacceptable that they are willing to discontinue treatment despite the potential for a decrease in survival. 10 The symptoms of CIPN are mainly sensory, with pain (including hypersensitivity to cool temperatures), tingling, and numbness (especially in the hands and feet), being the predominant complaints. [9] [10] [11] The distal distribution of the sensory complaints reflects the fact that large sensory nerve fibers are most commonly affected. In fact, dorsal root ganglion (DRG) neurons are a prominent target, possibly due to the fact that they are less protected by the blood-brain barrier. 8, 11 Motor symptoms are also encountered and include weakness, cramps, and gait dysfunction; sweating abnormalities, constipation, and light-headedness are evidence of autonomic symptoms. 8, 9 The symptoms of CIPN can be clinically assessed and graded. While there are several grading scales (including specific chemotherapy symptom scales), the two commonly employed scales are: (1) The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE or just NCI) and (2) The Total Neuropathy Score. Both scales are graded from 0 to 4 for each effect measured, with 4 indicating the greatest degree of severity. The NCI scale has a limited scoring range (0-4) because it only takes into account sensory effects and requires significant training to obtain high user reliability; in contrast, the Total Neuropathy Score scale has a wider scoring range (0-32 in total) as it includes sensory symptoms, motor symptoms, pin sensitivity, vibration sensitivity, strength, deep tendon reflexes, and neurophysiological effects from the sural and peroneal nerve and is considered reliable, having a high inter-observer reliability. 11, 12 The lack of a standardized approach to assess or grade CIPN can lead to variability in determining the prevalence of CIPN. 11, 13 Depending on the drug regimen, the overall rate of CIPN ranges from 19% to 85%. 13, 14 The incidence rate, however, is time sensitive; Seretny et al. 13 compiled data from 31 different studies and found that within the first month following chemotherapy treatment, $68% of patients had CIPN, by three months, 60% still had CIPN, and after six months, 30% were still affected. Another reason for the variability in the rate of occurrence may be due to differences in the chemotherapeutics themselves. As noted above, the three main chemotherapeutic classes commonly associated with CIPN are as follows: taxanes, platinum-based agents, and vinca alkaloids. The taxanes, which include paclitaxel, docetaxel, and cabazitaxel, are used to treat breast, ovary, non-small cell lung, gastric, head and neck, and prostate cancers. In contrast, platinum drugs, including cisplatin, carboplatin, and oxaliplatin, are used to treat cancers localized to the testes, ovary, cervix, uterus, head and neck, colon, and prostate. Finally, the vinca alkaloids, which include vincristine, vinblastine, vindesine, and vinorelbine, target hematologic cancers and pediatric sarcomas. Each antineoplastic class has a different mechanism of action and dose/rate of CIPN occurrence; it is therefore crucial to assess each one individually in order to reveal unique and/or common mechanisms involved in the pathogenesis of CIPN. One common mechanism to all three antineoplastic classes is changes in ion channel expression in primary afferent sensory neurons. In this review, we focus on this common pathway and review data from pre-clinical animal models as well as data from human studies where such exists. By better understanding common pathways, it may be possible to develop appropriate strategies to treat CIPN, or even better, prevent its onset.
Taxanes
Taxanes exert their effect by preventing the depolymerization of microtubules, leading to both apoptosis and the inhibition of axonal protein transport, thereby altering the function of distal sensory axons, either or both of which can result in CIPN. 8, 9, 15 The incidence of CIPN can vary depending on the dose per cycle, duration of infusion, cumulative dose, and treatment schedule, with paclitaxel more likely than docetaxel to cause CIPN. 10, 11, 16 
Paclitaxel
The incidence of paclitaxel-induced CIPN varies as a consequence of a number of factors: (1) the cumulative dose, the total dose at which CIPN symptoms first appear is >300 mg/m 2 , while a dose between 1400 and 1500 mg/m 2 has been linked to Grade 3 neuropathy; (2) rapid rate of infusion, there is increased neuropathy with a 3 h versus 24 h infusion duration; and (3) increased single dose, symptoms can start 24 to 72 h after administration of a single (high) dose of 250 mg/m 2 but usually occurs after multiple doses of the conventional dose of <200 mg/m 2 .
developed numbness in the hands and feet 18 ; the duration and incidence of CIPN may also be influenced by the specific cancer under treatment as Pignata et al. 19 reported that in patients with ovarian cancer, the probability of having CIPN after six months was 15% and 11% after two years. Alternatively, the differences in the incidence rates could also reflect drug-drug interactions as patients in the Pignata study received both carboplatin and paclitaxel. On average, while 50% of patients with paclitaxel-induced CIPN show recovery after nine months, roughly 40% of patients still display symptoms after three years. 8, 10, 11 Docetaxel Docetaxel-associated CIPN occurs at cumulative doses of >100 mg/m 2 , is milder than that associated with paclitaxel, and can resolve spontaneously following cessation of therapy. 10, 16 In contrast to paclitaxel, Grade 3/4 neuropathy occurs in <10% of patients, but is proportional to cumulative dose. 10, 16 While it may not be as severe as paclitaxel, up to one-third of patients treated with docetaxel will have CIPN that persists anywhere from 3 to 13 years after completing treatment. 20, 21 Therefore, even ''mild'' to ''moderate'' CIPN can still affect a large number of patients for extended periods of time and further underscores the need for effective treatments and/or protective strategies.
Platinum compounds
Platinum compounds, including carboplatin, cisplatin, and oxaliplatin, form platinum adducts that promote cross linking that can alter nuclear DNA structure and synthesis, 22, 23 as well as mitochondrial DNA, leading to oxidative stress. 9, 17 As a class, they contribute to the development of CIPN by impairing the electrophysiologic function of DRG neurons as demonstrated by a reduction and/or loss of the sensory action potential in nerve conduction studies. 9 Compared to cisplatin and oxaliplatin, carboplatin-induced CIPN is less severe and less common, occurring in 4% to 6% of patients.
10,24

Cisplatin
The risk of developing cisplatin-induced CIPN increases with cumulative dose and higher single dose administration. 8, 11, 25 The cumulative dose associated with risk of neurotoxicity is >350 mg/m 2 . 26 A common experience with cisplatin is the phenomenon known as ''coasting,'' wherein CIPN symptoms can worsen or start after completion of therapy. 10 Recovery is quite prolonged and is often incomplete, largely due to the fact that the platinum adducts can persist in body tissues for years. 27 When patient serum was tested 20 years after treatment, platinum levels were still elevated and the levels were associated with the severity of neuropathy. 28 Thus, it is not surprising that studies have found patients suffering from CIPN long after their treatment has ended. One such study found 20% of patients treated with cisplatin had persistent sensory neuropathy, 26 while another reported that overall, 80% of patients had demonstrable nerve damage, with 28% of patients remaining symptomatic 15 years after treatment, with 6% having severe, disabling CIPN. 9, 11, 29 
Oxaliplatin
The incidence of CIPN after oxaliplatin treatment also increases with cumulative dose, single dose, and rapid infusion rate. 11, 30, 31 Severe neuropathy occurs in 10% of patients after nine cycles of chemotherapy and up to 50% of patients after 14 cycles. 32 The cumulative dose associated with peripheral neuropathy is >550 mg/m 2 , 9, 11, 15 and with a cumulative dose of 750 to 850 mg/m 2 , 82% to 93% of patients experience some form of CIPN, with 12% to 34% of patients experiencing severe (Grade 3/4) neuropathy. 10, 11, 32, 33 Oxaliplatin-induced neuropathy is characterized by two distinct syndromes. First, there is the acute syndrome (which appears to be unique to oxaliplatin among the platinum compounds), which occurs during or immediately after administration of oxaliplatin, is seen in the majority of patients (85%-95%), can be triggered by cold, is characterized by neuronal hyperexcitability, and can resolve in hours or days after onset. [34] [35] [36] [37] Second, there is a chronic syndrome, which is comparable to the neuropathy seen with cisplatin and other platinum compounds where ''coasting'' occurs. 9, 35 This chronic syndrome can affect 80% to 90% of patients, with 40% to 50% of patients experiencing at least Grade 2 symptoms, while 10% to 20% had Grade 3 or 4 symptoms. 10, 35, 38 Although oxaliplatin-induced CIPN is largely reversible with an average time of recovery of 13 weeks, some patients experience persistent neuropathy. 11 It is important to note that what patients report (i.e., what is their subjective experience of their disease) is not necessarily the same as that which is ''objectively'' measured clinically. Objective assessment, such as with doctor scored NCI assessment or via nerve conduction studies, indicates that lasting abnormalities and decreased sensory amplitudes can be detected in 10% to 75% of patients up to six years after treatment is terminated. 9, 31, 39, 40 But this is not necessarily a foolproof diagnostic tool. Thus, one study reported that on clinical assessment with the NCI scale, 10% of patients will have objective measures consistent with a diagnosis of CIPN two years after treatment has ended even though 60% of patients will report symptoms consistent with lasting neuropathy when asked to describe how they are feeling 41 ; elsewhere, patients have reported significant symptoms up to 11 years after treatment ended, 42 again indicating that clinical assessment does not fully account for what the patient is experiencing. Conversely, there are instances where the incidence of patient reports of neuropathic symptoms is less than that as evidenced by altered nerve conduction studies; in that same study by Bennett et al., 41 while 60% of patients reported lasting neuropathy symptoms, 85% of patients demonstrated signs of neuropathy as measured via nerve conduction studies, suggesting that some patients with chronic symptoms may learn to ''adapt'' to their sensory abnormalities.
11 Such discordance demonstrates the need for improving our clinical assessment tools and/or the need to more adequately account for a patient's subjective experience when diagnosing CIPN.
Vinca alkaloids
Vincristine, one of the vinca alkaloids, is among the more toxic chemotherapy agents, and nearly all patients treated with vincristine develop some degree of neuropathy. 9, 10 Vincristine produces a loss of microtubules by preventing tubulin polymerization, which results in impaired axonal transport. 9, 10 Patients with vincristineinduced neuropathy have reduced amplitudes of both motor and sensory action potentials as well as slightly reduced conduction velocities. 9 The toxicity due to vincristine is both cumulative and dose dependent, with a dose-related threshold of >4 mg/m 2 and severe neuropathy occurring after a cumulative dose of 15 to 20 mg/m 2 . [9] [10] [11] 43, 44 Similar to cisplatin, ''coasting'' is common to patients treated with vincristine; it is seen in approximately 30% of patients, and the most common symptoms experienced are numbness and tingling in the hands and feet, which are seen in 35% to 45% of patients. [9] [10] [11] 43, 44 At least one study has suggested that vincristine-induced CIPN is largely reversible with good long-term prognosis, 10 whereas others studies have found that vincristineinduced CIPN persists for extended periods of time.
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Mild sensory symptoms were seen in 32% of nonHodgkin lymphoma survivors 34 months after the end of treatment, while 14% still had symptoms after nine years. 11, 45 In addition, 30% of children with acute lymphoblastic leukemia still had CIPN symptoms seven years after the end of treatment. 46 These studies are a reminder that while the prognosis (in terms of survival) may be good for the majority of vincristine-induced neuropathy patients, there are still many that suffer with a diminished long-term QoL and who need effective treatment for their neuropathy.
Despite the fact that distinct chemotherapeutic agents have different modes of action, many produce a longlasting peripheral neuropathy, which has significant public health ramifications. No uniformly effective treatments for CIPN exist, indicating that there is a pressing need to develop effective therapeutic strategies. There is increasing evidence that pain, both physiologic and pathologic, is associated with ion channel regulation and/or modulation to regulate neuronal activity in the peripheral nervous system. 47 Therefore, a clear understanding of how the functional expression of major neuronal ionic channels is altered by chemotherapy-related drugs will ideally reveal novel therapeutic targets that will help prevent or treat CIPN (Tables 1 and 2) . It is also possible that chemotherapy drugs do not act directly on ion channels, and second messengers such as cytokines could provide a link between the two as they are already implicated in pain 82, 83 and ion channel regulation. 84, 85 Therefore, the aim of this article is to review current research in the context of neuronal ion channels and pathways that are modulated by chemotherapeutic agents with the hope that it will reveal new and unappreciated research areas that warrant further investigation.
Neuronal excitation
Action potentials (APs) can encode information in their firing frequency and pattern, and perpetuate signal transmission as they propagate down the nerve axon and invade the axon terminal, where the resulting membrane depolarization initiates the sequence of steps necessary for vesicle mobilization, fusion, and exocytosis. APs are generated by the activation of ion channels. There are three main phases of the AP: (1) the depolarization phase-which consists of the upstroke and overshoot where the membrane potential becomes positive, (2) the repolarization phase-which consists of the downstroke after the depolarization phase and returns the cell's membrane potential to a negative potential (resting membrane potential), and (3) the after-hyperpolarization phase (AHP)-which is when the membrane potential falls below the resting membrane potential before returning to the resting state. Different ion channels are responsible for generating and sustaining the different phases. 86 Voltage-gated Na þ channels mediate the depolarization phase, voltage-gated Ca 2þ and K þ channels mediate the repolarization phase, K þ channels are responsible for the AHP, and K þ , Na þ , and HCN channels are responsible for setting the resting membrane potential, all of which help control the excitability of neurons. 86 We will briefly discuss each of these ion channel families, as well as Transient Receptor Potential (TRP) channels, and their role in CIPN.
Sodium channels
Biophysics
Voltage-gated Na þ (Na V ) channels are one of the more prominent ion channels associated with CIPN. The first indications of their involvement come from studies where administration of oxaliplatin increased the time course and amplitude of compound action potentials in A-fibers of rat sural and vagal nerves, indicating that Na V (with possible effects on K V channels as well) were modulated by this agent. 87 The Na V family consists of nine members; six members are sensitive to the organic blocker tetrodotoxin (TTX) (Na V 1.1-1.4, 1.6, and 1.7), and three are insensitive (Na V 1.5, 1.8, and 1.9). 88 Subsequent research turned to studying this modulation in heterologous expression systems in order to obtain greater mechanistic insights into chemotherapeutic modulation of Na V channel function.
At the biophysical level, oxaliplatin can decrease the peak amplitude of Na þ currents in NG108-15 neuronal cells (and in HEK293 cells in which Na V 1.5 channels were heterologously expressed). 66 Oxalate, but not dichlorodiaminocyclohexane platinum (which are the two main metabolites of oxaliplatin) decreases total Na þ currents in a Ca 2þ -dependent manner, suggesting that Na þ current inhibition by oxaliplatin results from Ca 2þ immobilization by oxalate. 89 In contrast, other groups have shown that oxaliplatin can shift the voltage of activation to more negative potentials as well as slow inactivation at negative membrane potentials, thereby leading to an increase in total Na þ current 56, 87, 90 and an increase in membrane excitability. 91 This oxaliplatin-induced stabilization of the open state occurs with Na V 1.6 channels. 56 
Animal studies
In vivo models of CIPN have added to our understanding of the important role that Na V channels play in the pathogenesis of CIPN. In general, TTX blocks the development of paclitaxel-induced mechanical and cold allodynia 69 and blocks oxaliplatin-induced nerve hyperexcitability in mice 90 ; those data emphasize that TTX-sensitive Na V channels play a key role in the development of CIPN.
Underscoring the role of Na V 1.6 in particular is the observation that oxaliplatin-induced increases in TTX-sensitive Na þ currents were absent in DRGs from Na V 1.6
mice. 56 The centrality of Na V 1.6 in this process is highlighted by additional gene deletion studies demonstrating that oxaliplatin-or vincristine-induced mechanical or cold allodynia is preserved in Na V 1.3, 1.7, 1.8, or 1.9 null mice. 77, 81 To exclude a role for these channels in CIPN may, however, be premature. Disease states that alter the expression and function of ion channels are not the same and may not produce the same physiological effect as [49] [50] [51] [52] 73 TRP channels TRPA1 À/À or inhibitor inhibits mechanical and cold allodynia and heat hyperalgesia 74, 75 TRPV4 inhibitor inhibits mechanical allodynia and heat hyperalgesia 74, 75 TRPV1 antagonists prevent thermal hyperalgesia and mechanical hypersensitivity 53, 75 Platinum deleting the channels before the actual disease or event occurs. 47 In support of this idea, genetic analysis of nociceptor ion channel expression in mice exposed to oxaliplatin detected an increase in Na V 1.8 mRNA, 62 while Na V 1.7 was increased following paclitaxel administration. 48 More compellingly, a tocainide-derived Na V 1.7-selective blocker, NeP1, produced anti-hyperalgesia after oxaliplatin administration. 63 The real test for in vivo target engagement is, of course, to test the efficacy of NeP1 in Na V 1.7 null mice following the induction of CIPN with oxaliplatin; those studies remain to be done.
A major complication with CIPN is cold hypersensitivity and cold-induced pain. In particular, the acute neuropathy caused by oxaliplatin is worsened by exposure to cold, and one study investigated the role oxaliplatin and its metabolites oxalate and dichlorodiaminocyclohexane platinum in both the acute (cold hyperalgesia/allodynia) versus chronic neuropathy (mechanical allodynia). 92 Sakurai et al. 92 found that oxalate, which can directly modulate Na V channels, contributes to the cold hyperalgesia/allodynia but dichlorodiaminocyclohexane platinum, which can bind DNA, contributes to mechanical allodynia but not coldinduced neuropathy suggesting a role for Na V channels in cold hyperalgesia/allodynia. In support of these findings, Na V channels have been shown to be modulated by cold and identified as cold sensors in nociceptive neurons.
65,93-95 TTX-sensitive channels, but not those that are TTX-insensitive, are inhibited by cooling temperatures, thus TTX-insensitive channels are still active at cooler temperatures and are responsible for mediating cold sensation and pain. 94 Two TTX-resistant Na V channels have been specifically attributed to sensing cold temperatures. Reducing temperatures shifts the voltage dependence of activation of Na V 1.8 to more negative potentials, thereby facilitating its activation and increasing neuronal excitability. 93 In addition, Na V 1.8 null mice showed no response to noxious cold and mechanical stimuli at low temperatures. 95 Like Na V 1.8, Na V 1.9 also shows increased activity in response to cool temperatures; thus, Na V 1.9 null neurons showed impaired firing in response to cold temperatures, and Na V 1.9 null mice and rats with Na V 1.9 knocked down demonstrated increased cold pain thresholds. In fact, disrupting Na V 1.9 alleviates oxaliplatin-induced cold hypersensitivity. 65 Interestingly, Na V 1.9 acts like an ''amplifier'' in cold sensing nociceptors by opening and producing a large sustained current near the resting potential, thereby amplifying sub-threshold depolarizations in the membrane potential produced by other colocalized ion channels, such as Na V 1.8, and increasing overall excitability. 65 In summary, the animal data strongly suggest that Na V 1.6 to 1.9 all contribute to CIPN in vivo.
Human studies
In addition to the in vitro and animal studies, there are human studies that further support the idea that Na V channels contribute to the development of CIPN. 36, 61, 96 Two independent studies investigated excitability and nerve conduction in patients who had received treatment with oxaliplatin. 36, 96 Knowing that Na V channels play an important role activating and shaping the AP, as well as establishing and maintaining the resting membrane potential, Krishnan et al. 96 used nerve conduction, specifically the compound AP measurements of the refractoriness and relative refractory period duration, to provide a connection between CIPN and Na V channel dysfunction. The relative refractory period is the time between APs when it is very difficult to generate another AP, and refractoriness is the percentage increase in current that is needed to generate an AP during the relative refractory period. Their results showed that oxaliplatin lead to increases in the refractoriness and relative refractory period, while patients were undergoing treatment and interestingly, they preceded the onset of clinical pain symptoms. 96 These increases were the result of acute administration of oxaliplatin, and it is known that oxaliplatin produces an acute pain syndrome that is caused by the oxaliplatin metabolite, oxalate, directly affecting Na V channels. 89 They also found that these early changes in the length of the median nerve AP refractory period were a predictor of the development of chronic neuropathy after oxaliplatin treatment, such that 78% of patients that had a refractory period of at least 4 ms (where normal duration is 3 ms), developed peripheral neuropathy, 96 suggesting early changes in Na V channels could lead to long-term CIPN. In a similar study, Park et al. 36 found that abnormalities in nerve excitability, specifically an increase in what they term ''superexcitability,'' or the period of time after the refractory period when it is much easier to generate an AP, of at least 15% that occurred early in treatment (prior to cycle 5) predicted the clinical outcome of moderate to severe paresthesia in 80% of patients. Collectively, these data indicate early or acute changes to Na V channels contribute to long-term CIPN in humans and may therefore represent relevant therapeutic molecular targets. But humans are not mice, so the question really becomes which human Na V channels are relevant?
To address this question, Argyriou et al. 61 conducted a prospective multicenter study to identify single nucleotide polymorphisms in Na V genes that could confer susceptibility to oxaliplatin-induced peripheral neuropathy. They found two polymorphisms, one in Na V 1.4, which is associated with increased incidence and severity of peripheral neuropathy, and the other in Na V 1.8, which is associated with increased incidence. That Na V 1.8 appears here is entirely congruent with the animal literature, while a role for Na V 1.4 may be species specific.
Potassium channels
Biophysics
While Na V channels are widely considered to be key to CIPN, K þ channels are controversial even though they contribute to the hyperexcitability observed in other pain syndromes. 97 In support, oxaliplatin application broadened the repolarization phase, and the AHP, and increased repetitive firing in rat peripheral myelinated nerve fibers, indicating that oxaliplatin-modulation of K þ channel inactivation was involved as channel inactivation shapes these electrical properties. 98 Further supporting a role of K V channels in CIPN, Benoit et al. 91 found that oxaliplatin blocked K þ channels and shifted the voltage dependence of activation to more negative potentials (although it is three times less effective at blocking K þ than Na þ currents). Additionally, oxaliplatin can inhibit delayed rectifier K þ current amplitude but did not affect their activation and inactivation in NG-108-15 cells. 66 In opposition, however, Adelsberger et al. 87 found that oxaliplatin did not affect K þ currents in rat nerve preparations, while other studies observed that application of K þ channel blockers (4-AP, tetraethylammonium, and apamin) did not replicate the effects of oxaliplatin on nerve hyperexcitability and could still block K þ currents after administration of oxaliplatin. 90 The biophysical data are equivocal with respect to supporting (or not) a role for K V channels in CIPN.
Animal studies
Despite the somewhat ambiguous biophysical results, data from animal models support a role for K þ channels in CIPN. The discordant results may arise from the fact that K þ channels are among a highly diverse class of ion channels, and in neurons alone, there are at least five different subfamilies: voltage-gated (K V ), Ca 2þ activated (K Ca ), inwardly rectifying (K ir ), two-pore (K 2P ), and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. 99 In rats given paclitaxel, contrasting changes in expression of a variety of K þ channel genes from multiple families were observed; specifically, there were increases in mRNA expression coding for K V 1.2, K V 11.3, K ir 3.1, and HCN1 channels along with reductions in K ir 1.1, K ir 3.4, and K 2P 1.1 mRNAs. 48 Notably, these changes were accompanied by a significant increase in excitability (as measured by AP firing and rheobase) in medium and large but not small, diameter nociceptors. Oxaliplatin also induced changes in K þ channel mRNA in mouse DRGs, with a down regulation of TREK1, TREK2, TRAAK, and K v 1.1 and an increase in HCN1. 62, 64 It is interesting that an increase in HCN1 mRNA appears to be a common feature across different classes of antineoplastics, suggesting that HCN1 channel regulation may represent a convergent pathway. HCN channels (HCN1-4) are activated by membrane hyperpolarization, are weakly selective for K þ over Na þ , and are the basis for the pacemaker current, I h , that contributes to the resting membrane potential and spontaneous firing in neurons. [100] [101] [102] [103] Mice treated with the nonisoform selective HCN channel blocker, ivabradine, did not experience oxaliplatin-mediated cold hypersensitivity and mechanical hyperalgesia (Figure 1) . 62, 78 Given the mRNA results demonstrating an apparent bias for HCN1, it would be worth testing an HCN1-selective channel blocker [104] [105] [106] [107] to determine the degree to which a single HCN channel isoform drives CIPN pathophysiology and whether highly restricted targeting represents a viable therapeutic strategy; proof of in vivo target engagement could make use of appropriate gene deletion mouse models.
Other K þ channels have also been implicated in CIPN. In rats, GIRK1/K ir 3.1 channels, which conduct an inward K þ current, are voltage independent, help maintain the resting membrane potential, 108 and are involved in the morphine-induced relief of oxaliplatinassociated neuropathy. 57 Interestingly, in a rat model of orofacial cold hyperalgesia induced by oxaliplatin, KCNQ (K V 7.1-7.5) channels (which help regulate neuronal excitability by contributing to the resting membrane potential 109, 110 ) are key mediators of this hyperalgesia. When the KCNQ blocker linopirdine 109 was injected into the orofacial region, it produced cold hyperalgesia (as demonstrated by reductions in total contact time with a cooling module); however, when the KCNQ activator retigabine 109 was given to rats treated with oxaliplatin, there was a reduction in cold hyperalgesia. 67 Finally, retigabine also partially restored nerve conduction properties and axon loss found in mice treated with cisplatin, indicating it could prevent CIPN. 68 Although these data strongly implicate K V 7 channels as contributing to CIPN, such an interpretation is based on the assumption that the in vivo pharmacology is unambiguous (which is often not as ''clean'' as one would like) and should be correlated with corresponding changes in mRNA and/or protein levels in order to make a more compelling argument in support of such a role.
K 2P potassium ''leak'' channels, yet another class of K þ channels involved in transducing noxious (i.e., painful) stimuli, conduct an outward K þ current that serves to hyperpolarize the resting membrane potential and help regulate neuronal excitability.
111 TREK1, TREK2, and TRAAK are members of the K 2P family and are thermosensitive channels that appear to play an important role in mediating cold hypersensitivity. 64, 93 TREK1 and TRAAK sense noxious cold temperatures, whereas TREK2 is involved in non-painful moderate cold sensation. 64 As noted above, cold intolerance is a common feature in patients with CIPN. When TREK2 knock-out mice were treated with oxaliplatin, they did not display chemotherapy-induced cool (i.e., at 20 C-25 C) hypersensitivity; in addition, wild-type mice treated with oxaliplatin, TREK2 mRNA was reduced by almost half in lumbar DRGs.
64 Double (TREK1-TRAAK) and triple (TREK1-TREK2-TRAAK) knock-out mice did not display oxaliplatin-mediated cold (i.e., at $15 C) hypersensitivity 62, 64 emphasizing the roles of TREK1 and TRAAK channels involvement in CIPN at cold temperatures, as opposed to TREK2 involvement in CIPN at cool temperatures.
Another temperature-sensitive class of K þ channels that may contribute to cold intolerance in CIPN belongs to the ''A-type'' K þ channel family. Several different channel proteins (including K V 1.4, K V 3.4, K V 4.1-4.3) conduct a rapidly activating and inactivating A-type K þ current (I A ) which helps regulate resting membrane potential, current threshold for AP generation, and AP repolarization. 112 I A currents were significantly reduced at 24 C (by 32%), severely reduced at 15 C (by 74%), and almost eliminated at 10 C (by 88%). 94 The inhibition of I A can cause hyperexcitability of neurons leading to cold hypersensitivity because I A essentially provides a brake for excitability; therefore, reduction of this current at cold temperatures releases that brake leading to membrane depolarization, which could then activate other channels. 94 Whether A-type K þ channels contribute to CIPN is unknown; if they do, however, the participation of K V 4.2 is questionable as its expression in DRG neurons is negligible. 113 
Human studies
One human study investigated the role of the small conductance Ca 2þ -dependent potassium channel, SK3 (K Ca 2.3), in oxaliplatin-induced neurotoxicity. 79 is essential for channel tetramerization. The study by Basso et al. 79 looked at sensory and motor nerve conduction before and after administration of oxaliplatin and found that patients treated with oxaliplatin that had neuropathy also had increased nerve hyperexcitability (manifested as increased amplitude of the compound AP, increased discharge and variable intraburst frequency). Interestingly, this nerve hyperexcitability was related to the length of the CAG repeats found in SK3; specifically, patients with short CAG repeats (13) (14) had increased nerve hyperexcitability. 79 These results suggest that the shorter CAG region impairs the assembly or function of SK3 channels resulting in improper AP AHP formation, thereby leading to the increased discharge seen in these studies. In summary, chemotherapeutic agents affect nearly all subfamilies of the K þ channel superfamily, suggesting that they are key elements in the development of CIPN, which could be considered legitimate molecular targets with respect to the development of new therapeutics.
Calcium channels
Ca 2þ signaling
While calcium channels (Ca V ) are known to be important contributors to pain signaling, 116 their role in CIPN has not been studied as extensively as that for Na V and K V channels. Ca V can be divided into two groups, high voltage activated and low voltage activated based on the voltage at which they open. 117 The Ca V 1 (L-type) and Ca V 2 (P/Q-, N-, and R-type) channels are members of the high-voltage activated group, and Ca V 3 (T-type) channels are the sole members of the low-voltage activated group. 118, 119 In addition to the pore forming a subunit, Ca V channels also consist of the b and a 2 d auxiliary subunits, which can enhance trafficking and channel expression as well as affect biophysical properties such as activation and inactivation. 117 Initial studies into the role of Ca V channels in CIPN focused on changes in intracellular Ca 2þ concentration, including influx through Ca V channels themselves as well as Ca 2þ efflux from mitochondria and other intracellular Ca 2þ stores. 120 In general, intracellular Ca 2þ regulation was shown to be disrupted after exposure to chemotherapy agents such as paclitaxel, vincristine, and oxaliplatin. 15, 120, 121 Additionally, administration of intracellular Ca 2þ chelators such as EGTA, TMB-8, and Quin-2 inhibited paclitaxel-and vincristine-induced mechano-allodynia and hyperalgesia in rats. 120 Since chemotherapeutic agents affected intracellular Ca 2þ to cause neuropathy, the next step was to determine if specific plasma membrane Ca V channels were involved.
Early research investigated global calcium entry via non-specific Ca V channels on the cell membrane. 122 Cisplatin was shown to reduce peak and sustained Ca 2þ currents in small diameter DRG neurons 122 ; in contrast, however, paclitaxel increased voltage-gated Ca 2þ currents in small and medium diameter rat DRG neurons. 49 These findings are important because small and medium diameter DRG neurons are responsible for conveying noxious sensory stimuli, suggesting these channels are important mediators of specific sensory abnormalities associated with CIPN. Recent studies have focused on the role of specific Ca V channels in the pathogenesis of CIPN. Short-term exposure of rat DRG to cisplatin resulted in a decrease in P/Q (i.e., Ca V 2.1), L-and T-type (i.e., Ca V 3.1-3.3), and Ca 2þ currents but an increase in the N-type currents. 55 N-type currents and protein levels are also increased after long-term exposure (24-48 h) to cisplatin. 55 Interestingly, there are differences as to how N-type currents are upregulated at these two time points. Short-term increase in N-type currents occurs via protein kinase C (PKC), but longterm changes are mediated via CaMKII. 55 Regulation of intracellular Ca 2þ has important consequences on cell survival as nimodipine, an L-type (i.e., Ca V 1.1-1.4) Ca 2þ channel inhibitor, or o-conotoxin, an N-type (i.e., Ca V 2.2) Ca 2þ channel inhibitor, reduce cisplatin-induced DRG neuronal death in vitro.
55,123
Animal models
In animal models of CIPN, cisplatin administration increased protein, but not mRNA levels of the N-type Ca V channel, indicating post-translational modifications were responsible for the observed effects. 55 Further supporting evidence for a role for N-type Ca V channels in CIPN can be found in studies with o-conotoxin, an N-type Ca V blocker that is clinically available as ziconotide (Prialt Õ , Jazz Pharmaceuticals, Dublin, Ireland) and used in the treatment of severe chronic pain. When o-conotoxin is administered before cisplatin treatment, it prevented upregulation in N-type Ca V channel expression and the development of neuropathic pain 55 ; when administered after paclitaxel treatment, it reduced acute mechanical hyperalgesia and prevented the worsening of chronic pain. 70 Likewise, Pha1b, a peptide toxin that blocks N-type Ca V channels (similar to o-conotoxin but with fewer side effects), can reduce paclitaxel-induced acute mechanical hyperalgesia and prevent the exacerbation of chronic pain in rats. 70 T-type Ca V channels also play an important role in CIPN. When the T-type Ca V 3.2 channel is knocked-down or pharmacologically blocked in a rat model of paclitaxel-induced peripheral neuropathy, antineoplastic-induced hyperalgesia is reversed. 71 Similarly, if the anti-epileptic T-type Ca V channel blocker ethosuximide is administered to rats after paclitaxel (or vincristine) treatment, it can reverse the induced mechanical allodynia, hyperalgesia, and cold allodynia. 72 Collectively, these results strongly suggest that changes in Ca V 2.2 and Ca V 3.2 expression or function contribute to CIPN.
A recent elegant study by Li et al. 54 further suggests the importance of Ca V 3.2 channels in CIPN. Paclitaxel increased Ca V 3.2 channel expression in small DRG neurons that were positive for calcitonin gene-related peptide and isolectin B4, anatomical markers of nociceptive neurons. 124 Following paclitaxel administration, acutely dissociated small diameter (<30 mm) DRG neurons were hyperexcitable (as measured by both spontaneous and depolarization-induced AP firing) compared to neurons obtained from vehicle-treated animals. These small diameter neurons also showed an increase in the T-type calcium current (as well as a shift in the activation curve to more negative potentials and a slowing of inactivation), contributing to increased Ca 2þ entry. 54 In vivo, paclitaxel-induced mechanical hypersensitivity was prevented by administration of the Ca V 3.2-specific inhibitor ML218 when administered to rats before and immediately after paclitaxel treatment, thereby providing additional support for a role of Ca V 3.2 in CIPN. 54 Previously, Li et al. 125 found that the toll-like receptor 4 (TLR4) contributed to paclitaxel-induced CIPN; consequently, they investigated its potential role in the increase in Ca V 3.2 expression and function. In the present study, the authors demonstrated that Ca V 3.2 and TLR4 co-localized to nociceptive neurons and can interact (as shown by co-immunoprecipitation). When a TLR4 inhibitor (TAK242) was administered to rats before and immediately after paclitaxel treatment, the results were similar to those obtained with ML218 described above, with a prevention of mechanical hypersensitivity. Collectively, these results suggest that paclitaxel acts via the TLR4 to upregulate Ca V 3.2 expression and function, which in turn results in spontaneous activity of DRG and neuropathic pain. 54 Finally, they were able to replicate the in vitro results using freshly obtained (i.e., non-cadaveric) human DRG neurons, thereby providing the necessary translational link which could support pursuing novel treatment strategies. 54 It is worth noting that the paclitaxel-induced hyperexcitability in DRG neurons decreased between post-treatment day 7 and day 14 (but not to baseline), suggesting that the initial hyperexcitability drives the development of CIPN, while the persistent excitability contributes to chronic neuropathic symptoms. If true, such a scenario has important implications with respect to the timing of any therapeutic intervention targeting Ca V channel-dependent hyperexcitability (and potentially the other ion channels as well), and that such intervention should be initiated prior to the start of chemotherapy and then continue throughout; how long after the end of chemotherapy such treatment should continue would depend on the pharmacokinetic profile(s) of the given antineoplastic regimen.
As mentioned above, Ca V channels have auxiliary b and a 2 d subunits that are important in channel expression and function. Interestingly, antineoplastics also alter a 2 d subunit expression. Oxaliplatin, cisplatin, and paclitaxel increase a 2 d expression in DRG neurons, [49] [50] [51] 55 while paclitaxel increases a 2 d expression in the dorsal horn. 50, 52 Gabapentin, a clinically relevant anti-epileptic drug that binds to the Ca V a 2 d subunit, 126 has been shown to have anti-hyperalgesic properties in CIPN. Thus, gabapentin has been shown to inhibit the paclitaxel-induced increase in Ca 2þ currents in rat DRG neurons, and it normalizes the accompanying paclitaxel-induced increase in a 2 d expression. 52 At the behavioral level, gabapentin reduced paclitaxel-, vincristine-and oxaliplatin-induced mechano-allodynia and hyperalgesia. 49, [50] [51] [52] 73 As the a 2 d subunit appears to bind with Ca V 1 and Ca V 2, but not Ca V 3, channels, 127, 128 these data strengthen the argument that Ca V 1 and Ca V 2 channels contribute to CIPN (but do not, of course, negate the results above implicating Ca V 3 channels as participants in CIPN pathophysiology).
Human studies
A small retrospective study of patients that underwent chemotherapy with oxaliplatin examined the relationship between Ca V blocker-administration (presumably administered for their antihypertensive properties) and the incidence of CIPN. 129 Ca V blockers included any one of the following: amlodipine (n ¼ 12), nifedipine (n ¼ 6), azelnidipine (n ¼ 2), diltiazem (n ¼ 1), benidipine (n ¼ 1), cilnidipine (n ¼ 1), nilvadipine (n ¼ 1), or amlodipine þ nilvadipine (n ¼ 1). Cumulative incidence curves were constructed whereby the probability of acute or chronic neuropathy was plotted against the cumulative dose of oxaliplatin, and the curves of the Ca V blocker group were compared to the control group. The results indicated that patients who took a Ca V blocker had a reduced incidence of acute, but not chronic, neuropathy. 129 On the surface, these data are encouraging when contemplating strategies to prevent the development of CIPN, but there is significant heterogeneity among the hypertensives used; while the majority of the drugs tested are L-type (Ca V 1) Ca V channel blockers, notable exceptions are amlodipine (N-and T-type, Ca V 2 and Ca V 3, respectively), benidipine (L-, N-, and T-type), cilnidipine (N-type), and nilvadipine (T-and L-type). [130] [131] [132] [133] [134] [135] Thus, drawing any firm conclusion as to which approach, if any, is the most viable is not possible; furthermore, the effect is only temporary. While this may have some value, it is by no means a panacea.
TRP channels
TRP channels are non-selective cation permeable channels that are highly permeable to Ca 2þ . 136 These channels are identified and classified into six subfamilies by their sequence homology to the trp gene originally found in Drosophila, and they included the following: (1) canonical (TRPC), (2) melastatin (TRPM), (3) vanilloid (TRPV), (4) ankyrin (TRPA), (5) mucolipin (TRPML), and (6) polycystin (TRPP). [136] [137] [138] Of those six families, only three are associated with pain, TRPV, TRPA, and TRPM channels. 139 Due to their permeability to Ca 2þ , these channels may also contribute to the Ca 2þ disruption caused by chemotherapy agents. 15, 120, 121 Furthermore, nine TRP channels contribute to thermoregulation and are activated by different temperatures, these channels are as follows: TRPV1, TRPV2, TRPV3, TRPV4, TRPM2, TRPM4, TRPM5, TRPM8, and TRPA1. 136, 137, 140 Of the nine, only two are activated by cold (<18 C) temperatures, TRPA1 and TRPM8, 136, 137 which suggests that they could contribute to CIPN-associated cold hypersensitivity or cold-induced pain. Consequently, TRP channels have become an important research area for uncovering the etiology of CIPN.
Animal studies
A number of studies have investigated the effect of antineoplastic drugs on the gene and protein expression levels of TRP channels. In this context, oxaliplatin was found to increase the mRNA and protein levels of TRPM8 in rat DRGs and plantar skin samples. [58] [59] [60] Furthermore, rats injected with oxaliplatin showed a peak increase in TRPM8 mRNA expression after three days which coincided with the peak of cold allodynia, 58 suggesting an important mechanistic link between CIPN and ion channel regulation. Similarly, paclitaxel has also been shown to increase the mRNA and protein levels of TRPV1 in DRGs 53 and the number of TRPV1-positive cells in DRG neurons. 125 Most of the studies on the role of TRP channels in CIPN utilize transgenic mice and channel agonists and antagonists to investigate the impact of chemotherapy agents. In one study, TRPA1 knock-out mice and the TRPA1 antagonist HC-030031 were used to block the rapid onset of oxaliplatin-and oxalate-induced cold hypersensitivity. 80 In another study, HC-030031 reversed oxaliplatin-induced mechanical and cold hyperalgesia in rats, and TRPA1 knock-out mice lacked oxaliplatininduced mechanical and cold hyperalgesia and displayed reduced cisplatin-induced mechanical allodynia. 76 A combination of TRPA1 and TRPV4 blockers (HC-030031 and HC-067047, respectively) completely inhibited paclitaxel-induced mechanical allodynia (which was only partially inhibited by each individual blocker). Further, paclitaxel-induced cold allodynia was markedly reduced in response to TRPA1 pharmacologic block or Trpa1 gene deletion. 74 The TRPM8 blockers ABMP and TC-I 2014 also stopped oxaliplatin-induced cold allodynia 60 ; while the TRPV1 antagonists capsazepine and AMG9810 prevented paclitaxel-induced thermal hyperalgesia and mechanical hypersensitivity, respectively. 53, 125 Finally, Chen et al. 75 utilized distinct blockers applied after paclitaxel administration to demonstrate a role for TRP channels in mechanical (TRPA1, TRPV4), and cold (TRPA1) allodynia, and heat hyperalgesia (TRPA1, TRPV4, TRPV1). Overall, the data from pre-clinical animal studies provide strong evidence in support of TRP channels contributing to CIPN.
Human studies
There are limited human data linking this class of ion channels to CIPN. In one study, Li et al. 125 used cultured human DRG neurons and demonstrated that paclitaxel activates and sensitizes TRPV1 channel responses. 125 In another clinical study, the TRPM8 activator menthol was used to assess the role of TRPM8 in CIPN. 141 In this study, menthol was applied to the tongues of healthy subjects and cancer patients before and after chemotherapy treatment with oxaliplatin and determined the cold sensation detection threshold, which is the minimum concentration of menthol needed to produce a cold sensation. The investigators found that there was a decrease in the cold sensation detection threshold after the oxaliplatin chemotherapy treatment, demonstrating hypersensitivity to cold and suggesting a mechanistic role for TRPM8 in CIPN. 141 Although there are strong indications from the pre-clinical animal literature that TRP channels contribute to CIPN, additional information is needed from human (or human tissue) studies to warrant pursuing this channel family as a therapeutic target in CIPN. If and when such data become available, TRP channels would clearly represent a novel target in the treatment of non-noxious temperature-dependent pain syndromes, including CIPN.
Second messenger pathways
The molecular mechanisms that underlie chemotherapyinduced changes in ion channel expression and function, and the resulting peripheral neuropathy, are poorly understood. Thus, even though platinum compounds as a class can produce CIPN, oxaliplatin, but neither cisplatin nor carboplatin, alters Na þ channel function, and this effect was recapitulated by oxalate but not by dichloro-diaminocyclohexane platinum. 89 Such a mechanistic divergence within drug class suggests that additional pathways may contribute to the development and/or maintenance of CIPN for any given drug class. Indeed, there are indications that these agents may mediate their effects through other cellular signaling pathways including those that involve pro-inflammatory cytokines, protein kinases, growth factors, and reactive oxygen species (ROS). 15, 73, 121, 142, 143 Importantly, these second messenger pathways can exert their effect by acting on ion channels. [143] [144] [145] [146] [147] For example, protein kinases such as adenosine monophosphate-activated protein kinase (AMPK), mitogen-activated protein kinase, protein kinase A (PKA), and PKC have all been shown to be involved in CIPN. 121, 143, 148 Concomitant administration of the oral hypoglycemic and AMPK activator metformin to mice with antineoplastics prevented development of mechanical hypersensitivity; such occlusion could result from either (1) mitogen-activated protein kinase-dependent changes in trafficking and/or phosphorylation or (2) AMPKdependent phosphorylation of ion channels. 143 In addition, PKA and PKCe antagonists can reduce paclitaxel (Taxol)-induced hyperalgesia, 148 and it has been shown that these kinases can modulate ion channel function, including HCN and Na V channels. 144, 145 We will further discuss specific pathways and their role in CIPN with regard to ion channels below.
Cytokines
Cytokines can be released by both glia and neurons and are important in pain pathways. 73 Chemotherapeutic agents induce the upregulation of macrophages leading to an elevated expression of pro-inflammatory cytokines, including TNFa, IL-1b, IL-6, and IL-8. 149 TNFa and IL-1b can sensitize A and C fibers and increase AP discharge via increases in the density of Na þ and Ca 2þ currents. 149 Further support for a role for TNFa comes from the observations that TNFa mRNA is increased in a mouse model of vincristine-induced CIPN, while inhibition of TNFa activity using an anti-TNFa antibody prevented mechanical allodynia. 150 In addition, TNFa has been shown to decrease Ca 2þ currents and increase Na þ currents when directly applied to nociceptive DRG neurons. 151 Finally, activation of TNF receptors increases Na þ currents in cultured rat DRG neurons. 146 With regard to chemotherapeutics, paclitaxel can induce expression of IL-1b, TNFa, and CD11b (a marker of immune cells/macrophages) mRNA in rat DRGs. 152 Moreover, blocking IL-1b with a receptor antagonist or adding the anti-inflammatory cytokine IL-10 reversed and/or prevented paclitaxel-induced mechanical allodynia and decreased the expression of IL-1b, TNFa, and CD11b. 152 Elsewhere it was demonstrated that paclitaxel-induced cold hyperalgesia depends on the chemokine (C-C motif) ligand 2 (CCL2) to activate the C-C chemokine receptor type 2 (CCR2), which in turn activates microglia, 153 and activated microglia are principal participants in the development and maintenance of neuropathic pain. 154 The link between microglia activation, cytokine release, and ion channel modulation is demonstrated by the observation that CCL2/CCR2 can activate PKC/NFkB which can, in turn, phosphorylate the Na V 1.8 channel leading to increased current density in inflammation-induced neuropathic pain 155 ; such results are entirely consistent with a role of cytokine-dependent signaling in CIPN. 156, 157 Another inflammatory cytokine that may also play a role in CIPN is IL-6, which is thought to be an important mediator in a wide variety of pathologic pain states. 158 IL-6 levels were found to increase in macrophages near the sciatic nerve and DRGs of mice after vincristine treatment. 159 The addition of an anti-IL-6 antibody, which prevents binding of IL-6 to its receptor (IL-6R), reduced mechanical allodynia after its development. 159 A similar picture also emerged in IL-6 knock-out mice treated with vincristine which displayed lower expression of mechanical allodynia. 159 Deletion of glycoprotein 130 (GP130), a membrane protein, and IL-6 receptor that mediates the effect of the IL-6-IL-6R complex, led to a reduction in mechanical and thermal hypersensitivity as well as altered excitability and potassium conductance of nociceptors; specifically, there is increased mRNA levels of Kcna4 and A-type K þ channel current density connecting cytokine signaling with regulating K þ channel function in nociceptor excitability and pain. 160 Finally, a breast cancer study that compared the expression of IL-6, and the soluble IL-6 receptor (sIL-6R) after chemotherapy found that painful CIPN was associated with elevated levels of IL-6/sIL-6R, and inversely correlated with QoL categories. 161 The occurrence of painful CIPN symptoms and the reduced QoL were linked to the activation of GP130 by the IL-6 and sIL-6R complex 161 ; which further demonstrates its contribution to CIPN and potential as a therapeutic target.
TRP channels and second messengers
The channel family that has been best studied with regard to second messenger modulation by antineoplastics are TRP channels, thereby possibly providing an interesting link between chemotherapy agents, second messenger modulation, ion channels, and CIPN. For example, paclitaxel can sensitize TRPV1 responses to capsaicin when TRPV1 is co-expressed with TLR4, a receptor that when activated triggers downstream mechanisms that lead to secretion of pro-inflammatory cytokines 162 in HEK293 cells, DRGs, and spinal neurons. 125 Interestingly, adding a TLR4 agonist can mimic these results, and a TLR4 antagonist prevents the increase in the number of TRPV1-positive neurons induced by paclitaxel. 125 In addition, TLR4 and TRPV1 are co-localized in rat and human DRG neurons. 125 These results suggest that paclitaxel acts via the TLR4 receptor to sensitize TRPV1 leading to neuropathic pain. TRPA1 channels are activated by oxidative stress and chemotherapeutics. Oxaliplatin can induce oxidative stress which results in the production of ROS 163 ; thus, TRPA1 may represent an important connection between oxidative stress, ROS, and CIPN. 15 For example, oxidative stress agents such as 4-hydroxynonenal and hydrogen peroxide act via TRPA1 and can cause cold hyperalgesia, which mimics oxaliplatin-induced cold hyperalgesia. 15, 164 In addition, antioxidants such as acetyl-L-carnitine, a-lipoic acid, or vitamin C inhibit oxaliplatin-induced hyperalgesia. 15, 165 Similar results were observed with paclitaxel and TRPA1. Paclitaxel increased the production of ROS, which in turn sensitized TRPA1 channels, while ROS scavengers were shown to block paclitaxel-induced mechanical hyperalgesia. 73 Chen et al. 75 conducted an elegant study piecing together a pathway from paclitaxel to neuropathic pain via the proteinase-activated receptor 2 (PAR2) pathway and TRP channels. 75 It is known that mast cells release tryptase, an activator of PAR2, and a sign of inflammation, 166 and PLC, PKC, and PKA are all downstream mediators of PAR2. PAR2 is expressed on DRG neurons, is co-expressed with TRPV1, TRPV4, and TRPA1 receptors, and can sensitize these channels via the PKA, PKC, and/or PLC pathway. 75, [167] [168] [169] Using a mouse model of paclitaxel-induced neuropathy, Chen et al. 75 observed increased release of tryptase from mast cells and an antagonist to PAR2 blocked pain behaviors. This study also found that blocking PLC lessened thermal hypersensitivity, whereas PKCe blockers inhibited mechanical allodynia and heat hyperalgesia, and PKA inhibitors reversed mechanical allodynia, heat hyperalgesia, and cold hyperalgesia. Overall, Chen et al. 75 found that mast cells release tryptase in response to paclitaxel which can then activate PAR2 initiating PKA, PKC, and PLC pathways which can then sensitize TRPV1, TRPV4, and TRPA1 leading to CIPN.
An important study linked Na V , Ca V , and TRP channels in the pathway that contributes to oxaliplatininduced cold hyperalgesia. 59 After application of oxaliplatin or oxalate to rat DRGs, Kawashiri et al. 59 observed cold hyperalgesia and a corresponding increase in TRPM8 mRNA, an increase in Ca 2þ influx, and the translocation of nuclear factor of activated T-cell (NFAT) to the nucleus, all of which were blocked by L-type Ca 2þ blockers (nifedipine or diltiazem) or the non-specific Na V channel blocker mexiletine. These results suggest that: (1) oxaliplatin increases Na þ currents (see above); (2) the increase in Na þ current enhances local depolarization in the membrane potential, which facilitates opening of co-localized L-type channels; (3) the increase in Ca V channel opening results in increased Ca 2þ influx; (4) the increase in intracellular Ca 2þ activates NFAT, which then translocates to the nucleus; (5) nuclear NFAT upregulates the expression of TRPM8; and finally, (6) an increase in TRPM8 in the DRG results in cold hyperalgesia.
Strategies to minimize CIPN
Conceptually, there are two ways to mitigate the debilitating effects of CIPN, one is to prevent the neuropathy prior to its onset and the other is to treat the neuropathy after it has developed. To date, although animal models of pain have provided crucial mechanistic insights into the molecular mechanisms of CIPN, whether and how these results will translate into human clinical advances is not yet clear. In this context, several case studies, small trials, and retrospective studies have provided evidence suggesting potential therapeutic strategies for CIPN. [170] [171] [172] [173] One case study found that the Na V blocker lacosamide 174 completely relieved neuropathic pain in patients following chemotherapy associated with vincristine and cisplatin. 175 In another study that utilized the anticonvulsant (and Ca V a 2 d channel blocker) pregabalin, patients displayed either complete resolution in their neuropathy or a significant reduction from Grade 3 to Grade 1. 176 Furthermore, in a study involving 23 patients, it was demonstrated that oxaliplatin-induced peripheral neuropathy was reduced in 48% of patients when pregabalin is given after the establishment of CIPN. 177, 178 While encouraging, absent large, prospective randomized, controlled trials, these and other data ''are insufficient to conclude that any of the purported chemoprotective agents. . . prevent or limit the neurotoxicity of platin drugs among human patients. '' 179 There is still controversy about the efficacy of treatment options for CIPN when expanded to full Phase III randomized, double-blinded studies. 170, 172, 173, 180, 181 For example, there have been contrasting reports on the impact of Ca 2þ /Mg 2þ infusions on treatment efficacy. In an early retrospective, non-randomized study, oxaliplatin patients who were given Ca 2þ /Mg 2þ infusions showed lower neuropathic intensity and recovered more rapidly from neuropathic pain. 182 In contrast, in a placebo-controlled double-blinded prospective trial, there were indications that Ca 2þ /Mg 2þ decreased the treatment efficacy of oxaliplatin, 183 leading to early termination; however, a further analysis of the results after the fact demonstrated that there actually was no decrease in treatment efficacy. 184 Another concurrent placebocontrolled randomized study was also terminated early because of the previous negative result; however, when the data were analyzed, the investigators observed a decrease in incidence of Grade 2 or greater sensory neuropathy. 185 Despite a few positive outcomes, there are still concerns with the Ca 2þ /Mg 2þ treatment strategy 17, 171, 186 as a large double-blind, randomized study showed no effect on oxaliplatin-induced peripheral neuropathy. 187 Similar to the Ca 2þ /Mg 2þ treatment, other ion channel modulators including carbamazepine, a Na V blocker, and gabapentin, a Ca V channel blocker, also showed promise in some trials 173 but not in others. 173, 188 Anti-oxidants as treatments have also demonstrated some initial positive results. 170, 173, 189 Amifostine, a free radical scavenger, showed some benefits in preliminary trials with small, but significant, reductions in neuropathy 190, 191 but were associated with side effects, 190 and other studies showed a lack of effect, 180, 192, 193 thus its use is not recommended. 186 The anti-oxidant, glutathione, also revealed mixed results. There were small randomized trials that showed some benefit [194] [195] [196] [197] ; however, a larger placebo-controlled study did not. 198 Another antioxidant and modulator of NGF, acetyl-L-carnitine had similar results, positive findings in small preliminary studies, 173, 199 which were not replicated in a larger doubleblind placebo-controlled study. 200 That early promising results could not be replicated in subsequent larger studies is not uncommon, 201 and the lack of reproducibility highlights the need to conduct large properly designed studies in the first place. [202] [203] [204] One treatment strategy recently made the transition from positive results in a preliminary trial to a large placebo-controlled trial. 205 Omega-3 fatty acids prevented paclitaxel-induced peripheral neuropathy in a small trial that included patients suffering from breast cancer. 206 Similar results were observed in a recent randomized, double-blind, placebo-controlled study on the effects of n-3 polyunsaturated fatty acids on oxaliplatin-induced peripheral neuropathy in patients with colon cancer. This study also showed a reduction in the incidence and severity of the neuropathy, 205 indicating polyunsaturated fatty acids warrant further investigation.
In 2014, the American Society of Clinical Oncology Clinical Practice published guidelines regarding the prevention and management of CIPN (Table 3) 186,207 ; they could not recommend a relevant drug option for the prevention of CIPN due to the lack of high-quality and consistent evidence for the distinct interventions. 186 However, duloxetine, a serotonin and norepinephrine dual re-uptake inhibitor, was their only treatment recommendation due to a positive Phase III clinical trial; it was a qualified recommendation, however, as duloxetine is not universally effective in that it was more effective . 211 Alterations in neuronal excitability can arise from changes in ion channel function at the level of the cell soma (located in the dorsal root ganglion; DRG), the axon terminal, or along the axon itself.
against oxaliplatin-induced CIPN than that induced by taxanes. 17, 186 While none of the current published studies have provided an appropriate therapy, there are currently over 30 clinical trials currently active regarding CIPN treatments which could provide promising results in the future. 208 So the important question is why is there a lack of high-quality consistent evidence? The lack of progress may be due to the fact that most of the studies that show positive results are generally associated with a small sample size, are un-blinded, or had no placebo controls, and the negative side effects of the agents are generally not reported. 17, 170, 186 Furthermore, there is also a lack of a universally agreed upon method to assess the occurrence of CIPN in clinical trials. Current CIPN assessment methods include physical exams, patient questionnaires, neuropathy scales and scores, nerve conduction studies, and quantitative sensory testing. 172 In addition, there are no standardized approaches to assess the efficacy of these drugs, with studies reporting a combination of symptom scores, clinical assessments, nerve conduction data, and results from quantitative sensory testing. 172 Therefore, it would be important to create a standardized method for the assessment of CIPN occurrence, as well as assessing the efficacy of the agent tested, in order to identify successful strategies for the prevention and/or treatment of CIPN. 209 
Conclusion/future directions
This review has highlighted data from animal and human studies implicating changes in primary afferent excitability resulting from alterations in ion channel expression and function as a common mechanism leading to the development of CIPN. While other mechanisms have been invoked (Figure 2) , 73, 156, 210 there are abundant data implicating ion channels (Tables 1  and 2 ) and second messengers such as cytokines in the development of CIPN. This is not an unexpected finding as changes in neuronal excitability appear to be a common feature of other neuropathic pain disorders including painful diabetic neuropathy and those associated with peripheral nerve injury. 47, 212, 213 While animal studies have provided many exciting positive results (reviewed by Hama and Takamatsu 214 ), the heralded promise of those results has not translated into positive results in human clinical trials. Is it possible that we have been focusing on the wrong targets? Conditional gene deletion (''knockout'') strategies to study the role of various proteins in neuropathic pain have been successfully employed, [215] [216] [217] [218] [219] [220] [221] [222] [223] all of which appear to confirm them as reasonable targets. One problem with the gene deletion approach, however, is compensatory up-or down-regulation of other channels or signaling cascades, resulting in cellular and/or synaptic homeostasis. [224] [225] [226] [227] As previously noted, another important consideration when interpreting gene deletion studies (at least as they relate to pain) is that the role of a given protein, be it an ion channel or enzyme, in pathologicalmediated neuropathic pain may not be equivalent to measuring the initiation/development of such pain when it is constitutively absent. 47 While there are important similarities in changes in ion channel protein expression between rodent and human sensory neurons, there may be just as important differences. These differences may account for the divergent results obtained with in vivo models examining new therapeutics for the treatment of neuropathic pain (see e.g., Jarvis et al. 227 and Ziegler et al. 228 ). The failure to translate the pre-clinical results into effective treatment strategies is multifactorial, with numerous potential solutions, including the development of more realistic pre-clinical models, 47 including the use of a non-human primate (NHP) model. 214, 229 In theory, an NHP-model might be an improvement over widely used rodent models, but the use of NHPs has been challenged on ethical and scientific grounds. 230 A viable and rapidly developing approach is to use a model that avoids the use of non-human tissues and which instead incorporates sensory neurons derived from human stem cells. 231, 232 Human stem cells, both embryonic stem cells or induced pluripotent, have been used as models of neurodegenerative disease and have provided promising results. 233 Pluripotent stem cells have also been suggested as an approach for studying ion channelopathies. 234 To date, though, there are few studies using human stem cells as a research paradigm for studying pain-related phenomona. 17, 233, 236 One such study found human fibroblast-derived nociceptors had functional TRPV1, TRPA1, and TRPM8 channels, generated TTX-resistant action potentials and phasic firing patterns characteristic of nociceptors, and when exposed to oxaliplatin, demonstrated sensitization of TRPV1. 236 Elsewhere, Wheeler et al. 233 successfully modeled CIPN with human-induced pluripotent stem cells. They found when cells were treated with paclitaxel, vincristine, or cisplatin, there were morphological differences in neurites including changes in outgrowth, process length, and outgrowth intensity. 233 The authors also knocked down the TUBB2A gene (whose expression has been shown to be associated with reduced risk of paclitaxel-induced neuropathy) in these cells and observed a reduction in neurite outgrowth after adding paclitaxel, suggesting an increased sensitivity to this chemotherapeutic agent. 233 Overall, these studies indicate that human stem cells could be a realistic pre-clinical human model for the study of CIPN.
At the in vivo level, neuroimaging techniques, including magnetic resonance imaging or positron emission tomography, can be used to investigate CIPN. [236] [237] [238] These techniques have been used to study pain across species, from rodent to humans, which makes it a particularly strong tool. Advantages of neuroimaging included the following: (1) the ability to follow the progression of the disease, (2) the ability monitor the network (rather than self-reported) response to various treatment strategies, and (3) utility in both pre-clinical and clinical research, thereby allowing direct correlation across in vivo models. 237, 239 Neuroimaging can even be informative at the molecular level, with the ability to image receptor distribution as well as ligand: receptor interactions and the corresponding signal transduction pathways. 237 Newer techniques using miniature optical imaging systems that can be attached to the head of awake, freely moving rodents have been developed, and this technology avoids the confounding effects of sedation and restraints routinely employed during in vivo imaging. 211 While these techniques have not been used to study CIPN, they could be an interesting new approach since they have been used successfully to study other pain syndromes.
In summary, CIPN is a pervasive condition that at present has no prevention and only one mildly recommended treatment strategy. 186 Despite the diversity of antineoplastic agents and their therapeutic mechanisms of action, one common theme contributing to the mutual pathophysiology of CIPN is their ability to modulate ion channel expression and function, either directly or through second messengers and inflammatory cytokines. Bridging the gap between the results obtained using the current pre-clinical models with those obtained thus far in humans will be necessary if we are to find effective strategies to treat, or even better, prevent, CIPN.
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